Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-12

AUTHORS

Ajai Chari, Daher Hajje

ABSTRACT

BACKGROUND: Carfilzomib is a selective proteasome inhibitor approved in the United States in 2012 for the treatment of relapsed and refractory multiple myeloma. Although cardiopulmonary and vascular events have been reported infrequently, they can be potentially serious complications, and their incidence and pathophysiology following carfilzomib treatment remain poorly characterized in a real-world patient population. METHODS: We retrospectively reviewed the records of 67 patients with relapsed and/or refractory multiple myeloma treated at our institution. RESULTS: We describe 12 patients who experienced cardiac or vascular-related adverse events subsequent to carfilzomib-based treatment (median age, 59 years [range, 49-77]). Nine patients had prior autologous stem cell transplant, and three had prior anthracycline exposure. Detailed case reports are provided for five representative patients: (1) systemic hypertension in a 65-year-old Caucasian female with a history of hypertension, hypothyroidism, and stage III chronic kidney disease; (2) pulmonary hypertension in a 72-year-old Caucasian male with a history of recurrent respiratory infections and chronic right lower extremity deep venous thrombosis; (3) acute renal insufficiency with increased blood pressure in a 50-year-old Caucasian male with a history of hypertension and stage IV chronic kidney disease; (4) heart failure in a 64-year-old African American female with a history of hypertension; and (5) dyspnea and lung disease in a 58-year-old Asian American male with a history significant for hepatitis B virus infection. CONCLUSIONS: While cardiac and vascular-related adverse events were reported in patients with relapsed and/or refractory multiple myeloma who were treated with carfilzomib, most patients had a history of the specific cardiac or vascular adverse event they exhibited and demonstrated an improvement or resolution in symptoms after the discontinuation of therapy. Appropriate screening and monitoring could potentially allow at-risk patients to benefit fully from treatment with carfilzomib. More... »

PAGES

915

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1471-2407-14-915

DOI

http://dx.doi.org/10.1186/1471-2407-14-915

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1043970134

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25471129


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multiple Myeloma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligopeptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vascular Diseases", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Icahn School of Medicine at Mount Sinai", 
          "id": "https://www.grid.ac/institutes/grid.59734.3c", 
          "name": [
            "Mt Sinai School of Medicine, 1 Gustave Levy Place, Box 1185, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chari", 
        "givenName": "Ajai", 
        "id": "sg:person.01307216512.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307216512.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "New York University", 
          "id": "https://www.grid.ac/institutes/grid.137628.9", 
          "name": [
            "New York University School of Medicine, 500 1st Avenue, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hajje", 
        "givenName": "Daher", 
        "id": "sg:person.0740741442.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740741442.46"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1074/jbc.m000155200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000396890"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/cvr/cvq217", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003711997"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1074-5521(99)80128-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005579611"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(11)70081-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006889817"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.111.039164", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007009347"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1078155210367839", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008412872"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1078155210367839", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008412872"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12012-011-9146-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009086166", 
          "https://doi.org/10.1007/s12012-011-9146-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.2013.089334", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010093517"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-09-0822", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010603266"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-6-129", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011079645", 
          "https://doi.org/10.1186/1471-2407-6-129"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2012-05-425934", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011406947"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clml.2012.08.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012352751"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1096/fj.03-0724rev", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014013190"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1096/fj.03-0054com", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014989100"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.112.047662", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017958620"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m602105200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018779970"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/fcp.12039", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021111026"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2013.29", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023785372", 
          "https://doi.org/10.1038/leu.2013.29"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2013.313", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026245496", 
          "https://doi.org/10.1038/leu.2013.313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2013.313", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026245496", 
          "https://doi.org/10.1038/leu.2013.313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-3007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026589995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-3007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026589995"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circresaha.107.152959", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028770923"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circresaha.107.152959", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028770923"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/cvr/cvp315", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030565949"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bbagrm.2010.09.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031585149"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/med.20111", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034042904"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2012-04-403733", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034167280"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/288373a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035626789", 
          "https://doi.org/10.1038/288373a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-010-0586-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039131435", 
          "https://doi.org/10.1007/s12185-010-0586-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12185-010-0586-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039131435", 
          "https://doi.org/10.1007/s12185-010-0586-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2012-03-414359", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040165478"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.freeradbiomed.2006.03.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041589119"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2012-06-437178", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042245975"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurjhf/hft034", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042957376"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2007.06659.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047036681"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-06-4086", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047843351"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2012-10-459883", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048110237"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2013.52.3522", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050316478"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/oxfordjournals.jbchem.a003139", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059959816"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.asn.0000132474.50966.da", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060319656"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.asn.0000132474.50966.da", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060319656"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/01.asn.0000132474.50966.da", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060319656"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1615/critrevimmunol.v21.i4.30", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1068131773"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075022499", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-12", 
    "datePublishedReg": "2014-12-01", 
    "description": "BACKGROUND: Carfilzomib is a selective proteasome inhibitor approved in the United States in 2012 for the treatment of relapsed and refractory multiple myeloma. Although cardiopulmonary and vascular events have been reported infrequently, they can be potentially serious complications, and their incidence and pathophysiology following carfilzomib treatment remain poorly characterized in a real-world patient population.\nMETHODS: We retrospectively reviewed the records of 67 patients with relapsed and/or refractory multiple myeloma treated at our institution.\nRESULTS: We describe 12 patients who experienced cardiac or vascular-related adverse events subsequent to carfilzomib-based treatment (median age, 59 years [range, 49-77]). Nine patients had prior autologous stem cell transplant, and three had prior anthracycline exposure. Detailed case reports are provided for five representative patients: (1) systemic hypertension in a 65-year-old Caucasian female with a history of hypertension, hypothyroidism, and stage III chronic kidney disease; (2) pulmonary hypertension in a 72-year-old Caucasian male with a history of recurrent respiratory infections and chronic right lower extremity deep venous thrombosis; (3) acute renal insufficiency with increased blood pressure in a 50-year-old Caucasian male with a history of hypertension and stage IV chronic kidney disease; (4) heart failure in a 64-year-old African American female with a history of hypertension; and (5) dyspnea and lung disease in a 58-year-old Asian American male with a history significant for hepatitis B virus infection.\nCONCLUSIONS: While cardiac and vascular-related adverse events were reported in patients with relapsed and/or refractory multiple myeloma who were treated with carfilzomib, most patients had a history of the specific cardiac or vascular adverse event they exhibited and demonstrated an improvement or resolution in symptoms after the discontinuation of therapy. Appropriate screening and monitoring could potentially allow at-risk patients to benefit fully from treatment with carfilzomib.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1471-2407-14-915", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "14"
      }
    ], 
    "name": "Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring", 
    "pagination": "915", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "d171ed24f52bc902c3ae05a10e15e64e67676937888b23d078b103edc944cfcc"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25471129"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1471-2407-14-915"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1043970134"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1471-2407-14-915", 
      "https://app.dimensions.ai/details/publication/pub.1043970134"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T17:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8672_00000515.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1471-2407-14-915"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-14-915'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-14-915'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-14-915'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-14-915'


 

This table displays all metadata directly associated to this object as RDF triples.

244 TRIPLES      21 PREDICATES      79 URIs      32 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1471-2407-14-915 schema:about N17255346597a43759c156ee869a95982
2 N1f35555c7cdc42ec949ab15953348daf
3 N1fbd0fc5cc7f43a796691dc77ad696c5
4 N6c33306d5e32444cb4c46e4c9813e281
5 N70fe9ddd66e34964ad35c50cd4977a15
6 N83f111bebf88402783fafdb3994e4b08
7 Na00683d53906414cbb13f6e33aa8b1e9
8 Nd2ae3a8a03ed4496be518dc70d682f35
9 Nd4db4cb9e7794aa695cb1f9f19439ac6
10 Nd6e31aabc41042de80e303b53759eb0c
11 Ne197b767d05543c9838dd8869e2d91a4
12 anzsrc-for:11
13 anzsrc-for:1102
14 schema:author N0097c8b547ac4330bf835aa6e5492c5d
15 schema:citation sg:pub.10.1007/s12012-011-9146-7
16 sg:pub.10.1007/s12185-010-0586-9
17 sg:pub.10.1038/288373a0
18 sg:pub.10.1038/leu.2013.29
19 sg:pub.10.1038/leu.2013.313
20 sg:pub.10.1186/1471-2407-6-129
21 https://app.dimensions.ai/details/publication/pub.1075022499
22 https://doi.org/10.1002/med.20111
23 https://doi.org/10.1016/j.bbagrm.2010.09.001
24 https://doi.org/10.1016/j.clml.2012.08.003
25 https://doi.org/10.1016/j.freeradbiomed.2006.03.003
26 https://doi.org/10.1016/s1074-5521(99)80128-8
27 https://doi.org/10.1016/s1470-2045(11)70081-x
28 https://doi.org/10.1074/jbc.m000155200
29 https://doi.org/10.1074/jbc.m602105200
30 https://doi.org/10.1093/cvr/cvp315
31 https://doi.org/10.1093/cvr/cvq217
32 https://doi.org/10.1093/eurjhf/hft034
33 https://doi.org/10.1093/oxfordjournals.jbchem.a003139
34 https://doi.org/10.1096/fj.03-0054com
35 https://doi.org/10.1096/fj.03-0724rev
36 https://doi.org/10.1097/01.asn.0000132474.50966.da
37 https://doi.org/10.1111/fcp.12039
38 https://doi.org/10.1111/j.1365-2141.2007.06659.x
39 https://doi.org/10.1124/dmd.111.039164
40 https://doi.org/10.1124/dmd.112.047662
41 https://doi.org/10.1158/0008-5472.can-06-4086
42 https://doi.org/10.1158/1078-0432.ccr-09-0822
43 https://doi.org/10.1158/1078-0432.ccr-11-3007
44 https://doi.org/10.1161/circresaha.107.152959
45 https://doi.org/10.1177/1078155210367839
46 https://doi.org/10.1182/blood-2012-03-414359
47 https://doi.org/10.1182/blood-2012-04-403733
48 https://doi.org/10.1182/blood-2012-05-425934
49 https://doi.org/10.1182/blood-2012-06-437178
50 https://doi.org/10.1182/blood-2012-10-459883
51 https://doi.org/10.1200/jco.2013.52.3522
52 https://doi.org/10.1615/critrevimmunol.v21.i4.30
53 https://doi.org/10.3324/haematol.2013.089334
54 schema:datePublished 2014-12
55 schema:datePublishedReg 2014-12-01
56 schema:description BACKGROUND: Carfilzomib is a selective proteasome inhibitor approved in the United States in 2012 for the treatment of relapsed and refractory multiple myeloma. Although cardiopulmonary and vascular events have been reported infrequently, they can be potentially serious complications, and their incidence and pathophysiology following carfilzomib treatment remain poorly characterized in a real-world patient population. METHODS: We retrospectively reviewed the records of 67 patients with relapsed and/or refractory multiple myeloma treated at our institution. RESULTS: We describe 12 patients who experienced cardiac or vascular-related adverse events subsequent to carfilzomib-based treatment (median age, 59 years [range, 49-77]). Nine patients had prior autologous stem cell transplant, and three had prior anthracycline exposure. Detailed case reports are provided for five representative patients: (1) systemic hypertension in a 65-year-old Caucasian female with a history of hypertension, hypothyroidism, and stage III chronic kidney disease; (2) pulmonary hypertension in a 72-year-old Caucasian male with a history of recurrent respiratory infections and chronic right lower extremity deep venous thrombosis; (3) acute renal insufficiency with increased blood pressure in a 50-year-old Caucasian male with a history of hypertension and stage IV chronic kidney disease; (4) heart failure in a 64-year-old African American female with a history of hypertension; and (5) dyspnea and lung disease in a 58-year-old Asian American male with a history significant for hepatitis B virus infection. CONCLUSIONS: While cardiac and vascular-related adverse events were reported in patients with relapsed and/or refractory multiple myeloma who were treated with carfilzomib, most patients had a history of the specific cardiac or vascular adverse event they exhibited and demonstrated an improvement or resolution in symptoms after the discontinuation of therapy. Appropriate screening and monitoring could potentially allow at-risk patients to benefit fully from treatment with carfilzomib.
57 schema:genre research_article
58 schema:inLanguage en
59 schema:isAccessibleForFree true
60 schema:isPartOf N858c8f791c014009b55acf37cbf6b8c8
61 Nedb631f0a9af48ad993676d2d3b26821
62 sg:journal.1024632
63 schema:name Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring
64 schema:pagination 915
65 schema:productId N08ff54d6ab35485f9f77d440929d3b97
66 N17c575e4e98e4bdda17791ce5bca0fd5
67 N757a23963042429f9c1a3b9f76e488b5
68 N7823a0b50008493faef5513a8623f786
69 Nc994d312e9b347d8bf7098a8c6ccbade
70 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043970134
71 https://doi.org/10.1186/1471-2407-14-915
72 schema:sdDatePublished 2019-04-10T17:32
73 schema:sdLicense https://scigraph.springernature.com/explorer/license/
74 schema:sdPublisher N2b9ae853eb534f89a3ad5c3e8c3fa934
75 schema:url http://link.springer.com/10.1186%2F1471-2407-14-915
76 sgo:license sg:explorer/license/
77 sgo:sdDataset articles
78 rdf:type schema:ScholarlyArticle
79 N0097c8b547ac4330bf835aa6e5492c5d rdf:first sg:person.01307216512.13
80 rdf:rest N18d6821251f241a58ff3fa3400ce31db
81 N08ff54d6ab35485f9f77d440929d3b97 schema:name doi
82 schema:value 10.1186/1471-2407-14-915
83 rdf:type schema:PropertyValue
84 N17255346597a43759c156ee869a95982 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Aged
86 rdf:type schema:DefinedTerm
87 N17c575e4e98e4bdda17791ce5bca0fd5 schema:name dimensions_id
88 schema:value pub.1043970134
89 rdf:type schema:PropertyValue
90 N18d6821251f241a58ff3fa3400ce31db rdf:first sg:person.0740741442.46
91 rdf:rest rdf:nil
92 N1f35555c7cdc42ec949ab15953348daf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Oligopeptides
94 rdf:type schema:DefinedTerm
95 N1fbd0fc5cc7f43a796691dc77ad696c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Heart Diseases
97 rdf:type schema:DefinedTerm
98 N2b9ae853eb534f89a3ad5c3e8c3fa934 schema:name Springer Nature - SN SciGraph project
99 rdf:type schema:Organization
100 N6c33306d5e32444cb4c46e4c9813e281 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Humans
102 rdf:type schema:DefinedTerm
103 N70fe9ddd66e34964ad35c50cd4977a15 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Antineoplastic Agents
105 rdf:type schema:DefinedTerm
106 N757a23963042429f9c1a3b9f76e488b5 schema:name readcube_id
107 schema:value d171ed24f52bc902c3ae05a10e15e64e67676937888b23d078b103edc944cfcc
108 rdf:type schema:PropertyValue
109 N7823a0b50008493faef5513a8623f786 schema:name nlm_unique_id
110 schema:value 100967800
111 rdf:type schema:PropertyValue
112 N83f111bebf88402783fafdb3994e4b08 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Multiple Myeloma
114 rdf:type schema:DefinedTerm
115 N858c8f791c014009b55acf37cbf6b8c8 schema:issueNumber 1
116 rdf:type schema:PublicationIssue
117 Na00683d53906414cbb13f6e33aa8b1e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Middle Aged
119 rdf:type schema:DefinedTerm
120 Nc994d312e9b347d8bf7098a8c6ccbade schema:name pubmed_id
121 schema:value 25471129
122 rdf:type schema:PropertyValue
123 Nd2ae3a8a03ed4496be518dc70d682f35 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Vascular Diseases
125 rdf:type schema:DefinedTerm
126 Nd4db4cb9e7794aa695cb1f9f19439ac6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Female
128 rdf:type schema:DefinedTerm
129 Nd6e31aabc41042de80e303b53759eb0c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Retrospective Studies
131 rdf:type schema:DefinedTerm
132 Ne197b767d05543c9838dd8869e2d91a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Male
134 rdf:type schema:DefinedTerm
135 Nedb631f0a9af48ad993676d2d3b26821 schema:volumeNumber 14
136 rdf:type schema:PublicationVolume
137 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
138 schema:name Medical and Health Sciences
139 rdf:type schema:DefinedTerm
140 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
141 schema:name Cardiorespiratory Medicine and Haematology
142 rdf:type schema:DefinedTerm
143 sg:journal.1024632 schema:issn 1471-2407
144 schema:name BMC Cancer
145 rdf:type schema:Periodical
146 sg:person.01307216512.13 schema:affiliation https://www.grid.ac/institutes/grid.59734.3c
147 schema:familyName Chari
148 schema:givenName Ajai
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307216512.13
150 rdf:type schema:Person
151 sg:person.0740741442.46 schema:affiliation https://www.grid.ac/institutes/grid.137628.9
152 schema:familyName Hajje
153 schema:givenName Daher
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740741442.46
155 rdf:type schema:Person
156 sg:pub.10.1007/s12012-011-9146-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009086166
157 https://doi.org/10.1007/s12012-011-9146-7
158 rdf:type schema:CreativeWork
159 sg:pub.10.1007/s12185-010-0586-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039131435
160 https://doi.org/10.1007/s12185-010-0586-9
161 rdf:type schema:CreativeWork
162 sg:pub.10.1038/288373a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035626789
163 https://doi.org/10.1038/288373a0
164 rdf:type schema:CreativeWork
165 sg:pub.10.1038/leu.2013.29 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023785372
166 https://doi.org/10.1038/leu.2013.29
167 rdf:type schema:CreativeWork
168 sg:pub.10.1038/leu.2013.313 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026245496
169 https://doi.org/10.1038/leu.2013.313
170 rdf:type schema:CreativeWork
171 sg:pub.10.1186/1471-2407-6-129 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011079645
172 https://doi.org/10.1186/1471-2407-6-129
173 rdf:type schema:CreativeWork
174 https://app.dimensions.ai/details/publication/pub.1075022499 schema:CreativeWork
175 https://doi.org/10.1002/med.20111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034042904
176 rdf:type schema:CreativeWork
177 https://doi.org/10.1016/j.bbagrm.2010.09.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031585149
178 rdf:type schema:CreativeWork
179 https://doi.org/10.1016/j.clml.2012.08.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012352751
180 rdf:type schema:CreativeWork
181 https://doi.org/10.1016/j.freeradbiomed.2006.03.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041589119
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1016/s1074-5521(99)80128-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005579611
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1016/s1470-2045(11)70081-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1006889817
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1074/jbc.m000155200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000396890
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1074/jbc.m602105200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018779970
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1093/cvr/cvp315 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030565949
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1093/cvr/cvq217 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003711997
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1093/eurjhf/hft034 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042957376
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1093/oxfordjournals.jbchem.a003139 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059959816
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1096/fj.03-0054com schema:sameAs https://app.dimensions.ai/details/publication/pub.1014989100
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1096/fj.03-0724rev schema:sameAs https://app.dimensions.ai/details/publication/pub.1014013190
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1097/01.asn.0000132474.50966.da schema:sameAs https://app.dimensions.ai/details/publication/pub.1060319656
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1111/fcp.12039 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021111026
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1111/j.1365-2141.2007.06659.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1047036681
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1124/dmd.111.039164 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007009347
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1124/dmd.112.047662 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017958620
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1158/0008-5472.can-06-4086 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047843351
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1158/1078-0432.ccr-09-0822 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010603266
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1158/1078-0432.ccr-11-3007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026589995
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1161/circresaha.107.152959 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028770923
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1177/1078155210367839 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008412872
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1182/blood-2012-03-414359 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040165478
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1182/blood-2012-04-403733 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034167280
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1182/blood-2012-05-425934 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011406947
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1182/blood-2012-06-437178 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042245975
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1182/blood-2012-10-459883 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048110237
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1200/jco.2013.52.3522 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050316478
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1615/critrevimmunol.v21.i4.30 schema:sameAs https://app.dimensions.ai/details/publication/pub.1068131773
236 rdf:type schema:CreativeWork
237 https://doi.org/10.3324/haematol.2013.089334 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010093517
238 rdf:type schema:CreativeWork
239 https://www.grid.ac/institutes/grid.137628.9 schema:alternateName New York University
240 schema:name New York University School of Medicine, 500 1st Avenue, New York, NY, USA
241 rdf:type schema:Organization
242 https://www.grid.ac/institutes/grid.59734.3c schema:alternateName Icahn School of Medicine at Mount Sinai
243 schema:name Mt Sinai School of Medicine, 1 Gustave Levy Place, Box 1185, New York, NY, USA
244 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...